Y Intercept Hong Kong Ltd Makes New Investment in Artiva Biotherapeutics, Inc. $ARTV

Y Intercept Hong Kong Ltd purchased a new position in shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) during the second quarter, Holdings Channel.com reports. The fund purchased 31,567 shares of the company’s stock, valued at approximately $48,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Charles Schwab Investment Management Inc. boosted its stake in Artiva Biotherapeutics by 26.1% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 54,881 shares of the company’s stock worth $165,000 after purchasing an additional 11,355 shares in the last quarter. Nuveen LLC acquired a new position in Artiva Biotherapeutics during the 1st quarter valued at approximately $144,000. Finally, Ground Swell Capital LLC purchased a new position in shares of Artiva Biotherapeutics in the second quarter worth $38,000.

Insider Activity

In other news, CEO Fred Aslan sold 25,500 shares of the company’s stock in a transaction dated Friday, October 17th. The stock was sold at an average price of $6.00, for a total value of $153,000.00. Following the sale, the chief executive officer owned 356,721 shares in the company, valued at $2,140,326. This represents a 6.67% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 21.40% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on ARTV shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Artiva Biotherapeutics in a report on Thursday, October 30th. Wedbush lifted their price target on Artiva Biotherapeutics from $18.00 to $23.00 and gave the stock an “outperform” rating in a research report on Friday, October 17th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $18.00 price objective on shares of Artiva Biotherapeutics in a report on Friday, October 17th. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $18.25.

Artiva Biotherapeutics Price Performance

NASDAQ ARTV opened at $3.46 on Monday. Artiva Biotherapeutics, Inc. has a 1 year low of $1.47 and a 1 year high of $14.22. The company has a market capitalization of $84.53 million, a PE ratio of -1.32 and a beta of 3.04. The company has a fifty day moving average of $3.34 and a 200 day moving average of $2.65.

Artiva Biotherapeutics Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.